(Q36905034)

17 August 2017

1 reference

title

The vasodilatory beta-blockers (English)

1 reference

17 August 2017

Michala E Pedersen

1

1 reference

17 August 2017

John R Cockcroft

series ordinal

2

1 reference

17 August 2017

publication date

1 August 2007

1 reference

Current Hypertension Reports

17 August 2017

published in

1 reference

17 August 2017

volume

9

1 reference

17 August 2017

issue

4

1 reference

17 August 2017

page(s)

269-277

1 reference

https://scigraph.springernature.com/pub.10.1007/s11906-007-0050-2

17 August 2017

exact match

0 references

cites work

Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11906-007-0050-2

The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11906-007-0050-2

Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11906-007-0050-2

Nebivolol: a third-generation beta-adrenergic blocker

21 January 2018

1 reference

12 December 2020

Labetalol compared with propranolol in the treatment of black hypertensive patients

1 reference

12 December 2020

Labetalol in the treatment of hypertension in elderly and younger patients

1 reference

12 December 2020

Atenolol and cardiovascular risk: an issue close to the heart

1 reference

12 December 2020

Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease

1 reference

12 December 2020

Partial regression of vascular structural alterations in hypertensive patients treated with alpha-beta-blocker, labetalol

1 reference

12 December 2020

Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).

1 reference

12 December 2020

Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients

1 reference

12 December 2020

Aortic pulse pressure is related to the presence and extent of coronary artery disease in men undergoing diagnostic coronary angiography: a multicenter study

1 reference

12 December 2020

A dose-response trial of nebivolol in essential hypertension.

1 reference

12 December 2020

Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity

1 reference

12 December 2020

Carvedilol action is dependent on endogenous production of nitric oxide

1 reference

12 December 2020

Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats.

1 reference

12 December 2020

Nebivolol improves coronary flow reserve in hypertensive patients without coronary heart disease

1 reference

12 December 2020

Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics

1 reference

12 December 2020

Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders

1 reference

12 December 2020

Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients

1 reference

12 December 2020

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

1 reference

12 December 2020

Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity

1 reference

12 December 2020

Current status of labetalol, the first alpha- and beta-blocking agent

1 reference

12 December 2020

Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis

1 reference

12 December 2020

Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes

1 reference

12 December 2020

Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study

1 reference

12 December 2020

The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension

1 reference

12 December 2020

Basal NO locally modulates human iliac artery function in vivo.

1 reference

12 December 2020

Atenolol in hypertension: is it a wise choice?

1 reference

12 December 2020

Anti-NO action of carvedilol in cell-free system and in vascular endothelial cells

1 reference

12 December 2020

Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study

1 reference

12 December 2020

Myocardial perfusion during long-term angiotensin-converting enzyme inhibition or beta-blockade in patients with essential hypertension.

1 reference

12 December 2020

Acute hemodynamic effects of the vasodilating and beta-blocking agent carvedilol in comparison to propranolol

1 reference

12 December 2020

Effects of two antihypertensive agents, labetalol and metoprolol, on the production of reactive oxygen species by normal polymorphonuclear leukocytes in vitro

1 reference

12 December 2020

Metabolic and antihypertensive effects of nebivolol and atenolol in normometabolic patients with mild-to-moderate hypertension

1 reference

12 December 2020

Role of vasodilation in the antihypertensive and antianginal effects of labetalol: implications for therapy of combined hypertension and angina

1 reference

12 December 2020

Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study.

1 reference

12 December 2020

Vasodilatation, not hypotension, improves resistance vessel design during treatment of essential hypertension: a literature survey

1 reference

12 December 2020

Monotherapy with labetalol compared with propranolol. Differential effects by race

1 reference

12 December 2020

Beta-adrenergic blocking drugs in the treatment of hypertension

1 reference

12 December 2020

Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension

1 reference

12 December 2020

Carvedilol and its metabolites suppress endothelin-1 production in human endothelial cell culture

1 reference

12 December 2020

The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study

1 reference

12 December 2020

Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients

1 reference

12 December 2020

In vitro and ex vivo antioxidant activities of labetalol on rabbit neutrophil respiratory burst

1 reference

12 December 2020

Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism

1 reference

12 December 2020

Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol

1 reference

12 December 2020

Effect of carvedilol and metoprolol on blood pressure, blood flow, and vascular resistance

1 reference

12 December 2020

Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients

1 reference

12 December 2020

Carvedilol inhibits vascular smooth muscle cell proliferation.

1 reference

12 December 2020

Effect of carvedilol on survival in severe chronic heart failure

1 reference

12 December 2020

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

1 reference

12 December 2020

Aortic pressure augmentation predicts adverse cardiovascular events in patients with established coronary artery disease

1 reference

12 December 2020

Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans

1 reference

12 December 2020

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

12 December 2020

Nebivolol increases arterial distensibility in vivo.

1 reference

12 December 2020

Prognostic significance of small-artery structure in hypertension.

1 reference

12 December 2020

The latest generation of beta-blockers: new pharmacologic properties

1 reference

12 December 2020

Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension?

1 reference

12 December 2020

Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial

1 reference

12 December 2020

Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation

1 reference

12 December 2020

The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with [...]

1 reference

12 December 2020

Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms

1 reference

12 December 2020

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

1 reference

12 December 2020

10.1007/S11906-007-0050-2

Identifiers

DOI

1 reference

17 August 2017

1 reference